Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

Research output: Contribution to journalJournal articleResearchpeer-review

  • Fumiyo Nakagawa
  • Rebecca Lodwick
  • Dominique Costagliola
  • Ard van Sighem
  • Carlo Torti
  • Daniel Podzamczer
  • Amanda Mocroft
  • Bruno Ledergerber
  • Maria Dorrucci
  • Alessandra Cozzi-Lepri
  • Klaus Jansen
  • Bernard Masquelier
  • Federico García
  • Stephane De Wit
  • Christoph Stephan
  • Obel, Niels
  • Gerd Fätkenhaeuer
  • Antonella Castagna
  • Helen Sambatakou
  • Cristina Mussini
  • Jade Ghosn
  • Robert Zangerle
  • Xavier Duval
  • Laurence Meyer
  • Santiago Perez-Hoyos
  • Céline Fabre Colin
  • Jesper Kjaer
  • Genevieve Chene
  • Jesper Grarup
  • Andrew Phillips
  • Pursuing Later Treatment Options II (PLATO II) project team
Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [triple-class virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years.
Original languageEnglish
JournalJ A I D S
Volume59
Issue number3
Pages (from-to)294-9
Number of pages6
ISSN1525-4135
DOIs
Publication statusPublished - 2012

ID: 48545407